Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. The agency granted Lenvima priority review as a treatment for advanced kidney cancer, which could be a much more lucrative indication. More than 61,000 patients will be diagnosed with kidney cancer this year, Eisai says; the approval would cover Lenvima in combination with Novartis' ($NVS) Afinitor in patients who've failed on previous VEGF therapy. Release

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.